<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03451786</url>
  </required_header>
  <id_info>
    <org_study_id>ONT-301-17</org_study_id>
    <nct_id>NCT03451786</nct_id>
  </id_info>
  <brief_title>Prospective Clinical Trial to Evaluate the Safety and Effectiveness of the IOL</brief_title>
  <official_title>A Multi-center, Prospective Clinical Trial to Evaluate the Safety and Effectiveness of a Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Estelle Poineau</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carl Zeiss Meditec AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the safety and effectiveness of the CT LUCIA 611P posterior chamber intraocular&#xD;
      lens for the correction of aphakia following extracapsular cataract extraction via&#xD;
      phacoemulsification in adult patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2018</start_date>
  <completion_date type="Actual">March 12, 2020</completion_date>
  <primary_completion_date type="Actual">March 12, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected distance visual acuity</measure>
    <time_frame>postoperative days 330-420</time_frame>
    <description>Proportion of subjects achieving BCDVA 0.3 logMAR or better</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">339</enrollment>
  <condition>Cataract Unilateral</condition>
  <condition>Aphakia</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IOL</intervention_name>
    <description>Intraocular lens</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, age 22 years or older at the time of study enrollment.&#xD;
&#xD;
          2. Visually significant cataract in the study eye for which phacoemulsification cataract&#xD;
             extraction and posterior chamber IOL implantation is indicated.&#xD;
&#xD;
          3. Projected postoperative BCDVA 0.20 logMAR or better in the study eye, as determined by&#xD;
             Investigator's medical judgment.&#xD;
&#xD;
          4. Calculated spherical power targeted at emmetropia at distance in the study eye.&#xD;
&#xD;
          5. Calculated IOL power between +4.0 D and +34.0 D, inclusive, in the study eye.&#xD;
&#xD;
          6. If wearing rigid gas permeable (RGP) contact lens in the study eye, willingness to&#xD;
             discontinue lens wear for â‰¥ 30 days prior to preoperative biometry.&#xD;
&#xD;
          7. Availability, willingness, and sufficient cognitive awareness to return for&#xD;
             study-required visits and comply with examination procedures.&#xD;
&#xD;
          8. Willingness to sign the IRB-approved informed consent form (ICF) for study&#xD;
             participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mature cataract in the study eye that is likely to prolong surgical procedure and/or&#xD;
             lead to intraoperative complications prior to attempted IOL implantation.&#xD;
&#xD;
          2. Planned cataract removal using a femtosecond laser.&#xD;
&#xD;
          3. Any visually significant intraocular media opacity other than cataract in the study&#xD;
             eye (as determined by the investigator).&#xD;
&#xD;
          4. Significant refractive error (hyperopia/myopia) of axial or pathologic origin in the&#xD;
             study eye that, in the judgment of the investigator, could confound outcomes.&#xD;
&#xD;
          5. Abnormal corneal findings in either eye (e.g. keratoconus, pellucid marginal&#xD;
             degeneration, or irregular astigmatism).&#xD;
&#xD;
          6. Any anterior segment pathology in the study eye that could significantly affect&#xD;
             outcomes (e.g. chronic uveitis, iritis, aniridia, rubeosis iridis, clinically&#xD;
             significant corneal or anterior membrane dystrophies, poor pupil dilation, etc.)&#xD;
&#xD;
          7. Any condition in the study eye that could affect IOL stability (e.g.&#xD;
             pseudoexfoliation, zonular dialysis, evident zonular weakness or dehiscence, etc.).&#xD;
&#xD;
          8. History of severe dry eye in the study eye that, in the judgment of the investigator,&#xD;
             would impair the ability to obtain reliable study measurements.&#xD;
&#xD;
          9. History of serious corneal disease (e.g., herpes simplex, herpes zoster keratitis,&#xD;
             etc.) in either eye.&#xD;
&#xD;
         10. History of any clinically significant retinal pathology or ocular diagnosis (e.g.&#xD;
             diabetic retinopathy, ischemic diseases, macular degeneration, retinal detachment,&#xD;
             optic neuropathy, amblyopia, strabismus, microphthalmos, aniridia, epiretinal membrane&#xD;
             etc.) in the study eye that could alter or limit final postoperative visual prognosis.&#xD;
&#xD;
         11. History of cystoid macular edema in either eye.&#xD;
&#xD;
         12. History of uveitis in either eye.&#xD;
&#xD;
         13. History of intraocular or corneal surgery in the study eye.&#xD;
&#xD;
         14. Uncontrolled glaucoma in the study eye (per Investigator judgment).&#xD;
&#xD;
         15. Current ocular infection in the study eye.&#xD;
&#xD;
         16. Fellow eye BCDVA worse than 1.0 logMAR.&#xD;
&#xD;
         17. Presence of uncontrolled systemic disease that could increase operative risk (e.g.,&#xD;
             diabetes mellitus, active cancer treatment, mental illness, dementia,&#xD;
             immunocompromised, connective tissue disease, clinically significant atopic disease,&#xD;
             etc.).&#xD;
&#xD;
         18. Use of or history of use of systemic medications with significant ocular side effects&#xD;
             or any medications that could confound the outcome or increase patient risk (e.g.,&#xD;
             steroids, Tamsulosin Hydrochloride [Flomax] or other medications including&#xD;
             anticholinergics or alpha-adrenergic blocking agents with similar side effects [e.g.&#xD;
             small pupil/floppy iris syndrome], anti-metabolites, etc.)&#xD;
&#xD;
         19. Participation in any other non-eye related drug or device clinical trial within 30&#xD;
             days prior to enrolling in this study and/or during study participation.&#xD;
&#xD;
         20. Participation in any eye-related drug or device clinical trial within 90 days prior to&#xD;
             enrolling in this study and/or during the study participation.&#xD;
&#xD;
         21. Planned concomitant ocular procedure during cataract surgery (e.g., glaucoma surgery&#xD;
             including implantation of MIGS, astigmatic correction surgery, penetrating&#xD;
             keratoplasty [PK], laser-assisted in situ keratomileusis [LASIK], etc.)&#xD;
&#xD;
         22. Pregnant, lactating or, if able to bear children, unwilling to use medically&#xD;
             acceptable birth control over the course of the study.&#xD;
&#xD;
         23. Unsuitable for study participation for any other reason, as determined by&#xD;
             Investigator's clinical judgment (reason to be documented on eCRF).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Argus Research at Cape Coral Eye Center</name>
      <address>
        <city>Cape Coral</city>
        <state>Florida</state>
        <zip>33904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>February 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <disposition_first_submitted>March 2, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>March 5, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 8, 2021</disposition_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Carl Zeiss Meditec AG</investigator_affiliation>
    <investigator_full_name>Estelle Poineau</investigator_full_name>
    <investigator_title>Clinical Project Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Aphakia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

